SK5562003A3 - EP4 receptor selective agonists in the treatment of osteoporosis - Google Patents

EP4 receptor selective agonists in the treatment of osteoporosis Download PDF

Info

Publication number: SK5562003A3
Authority: SK; Slovakia
Prior art keywords: prodrugs; compounds; alkyl; bone; phenyl
Prior art date: 2000-11-27

Application number

SK556-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Kimberly O'keefe Cameron

Bruce Allen Lefker

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-27

Filing date

2001-11-05

Publication date

2004-08-03

2001-11-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-08-03 Publication of SK5562003A3 publication Critical patent/SK5562003A3/sk

Links

208000001132 Osteoporosis Diseases 0.000 title claims abstract description 45
238000011282 treatment Methods 0.000 title claims description 24
239000000556 agonist Substances 0.000 title abstract description 43
101150109738 Ptger4 gene Proteins 0.000 title abstract description 10
150000001875 compounds Chemical class 0.000 claims abstract description 246
210000000988 bone and bone Anatomy 0.000 claims abstract description 135
208000010392 Bone Fractures Diseases 0.000 claims abstract description 50
241000124008 Mammalia Species 0.000 claims abstract description 21
206010065687 Bone loss Diseases 0.000 claims abstract description 20
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
230000007547 defect Effects 0.000 claims abstract description 6
208000002679 Alveolar Bone Loss Diseases 0.000 claims abstract description 5
208000001164 Osteoporotic Fractures Diseases 0.000 claims abstract description 4
201000001245 periodontitis Diseases 0.000 claims abstract description 4
-1 (C 2 -C 7) -alkenyl Chemical group 0.000 claims description 174
239000000651 prodrug Substances 0.000 claims description 147
229940002612 prodrug Drugs 0.000 claims description 147
150000003839 salts Chemical class 0.000 claims description 107
239000000203 mixture Substances 0.000 claims description 87
229910052757 nitrogen Chemical group 0.000 claims description 45
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 40
125000000217 alkyl group Chemical group 0.000 claims description 36
QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims description 29
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 26
229920006395 saturated elastomer Polymers 0.000 claims description 24
229910052799 carbon Inorganic materials 0.000 claims description 20
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
125000001153 fluoro group Chemical group F* 0.000 claims description 19
125000003545 alkoxy group Chemical group 0.000 claims description 16
125000001424 substituent group Chemical group 0.000 claims description 16
125000004093 cyano group Chemical group *C#N 0.000 claims description 14
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 12
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
229910052760 oxygen Inorganic materials 0.000 claims description 11
239000001301 oxygen Substances 0.000 claims description 11
239000011593 sulfur Chemical group 0.000 claims description 11
229910052717 sulfur Inorganic materials 0.000 claims description 11
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 9
125000001589 carboacyl group Chemical group 0.000 claims description 9
125000004043 oxo group Chemical group O=* 0.000 claims description 9
125000001544 thienyl group Chemical group 0.000 claims description 9
125000002619 bicyclic group Chemical group 0.000 claims description 8
239000000460 chlorine Substances 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
125000001309 chloro group Chemical group Cl* 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
150000002367 halogens Chemical group 0.000 claims description 7
125000005842 heteroatom Chemical group 0.000 claims description 7
125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 6
125000003282 alkyl amino group Chemical group 0.000 claims description 6
125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 6
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 6
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 5
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
125000005236 alkanoylamino group Chemical group 0.000 claims description 5
125000006598 aminocarbonylamino group Chemical group 0.000 claims description 5
229910052801 chlorine Inorganic materials 0.000 claims description 5
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 4
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
125000004414 alkyl thio group Chemical group 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
230000000366 juvenile effect Effects 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000002950 monocyclic group Chemical group 0.000 claims description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
125000000335 thiazolyl group Chemical group 0.000 claims description 3
125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
125000002541 furyl group Chemical group 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
125000003396 thiol group Chemical class [H]S* 0.000 claims 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
238000000034 method Methods 0.000 abstract description 124
150000003180 prostaglandins Chemical class 0.000 abstract description 24
208000036119 Frailty Diseases 0.000 abstract 1
206010003549 asthenia Diseases 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 527
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 333
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 327
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 199
235000019439 ethyl acetate Nutrition 0.000 description 188
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 130
238000005481 NMR spectroscopy Methods 0.000 description 104
239000000243 solution Substances 0.000 description 101
238000004587 chromatography analysis Methods 0.000 description 98
239000002609 medium Substances 0.000 description 91
238000000746 purification Methods 0.000 description 85
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 75
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 69
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 68
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 54
238000006243 chemical reaction Methods 0.000 description 54
239000011541 reaction mixture Substances 0.000 description 48
206010017076 Fracture Diseases 0.000 description 47
230000002829 reductive effect Effects 0.000 description 47
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 46
239000002904 solvent Substances 0.000 description 41
MNWFXJYAOYHMED-UHFFFAOYSA-N hexane carboxylic acid Natural products CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 39
238000002360 preparation method Methods 0.000 description 39
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
229940011871 estrogen Drugs 0.000 description 34
239000000262 estrogen Substances 0.000 description 34
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 34
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
239000012442 inert solvent Substances 0.000 description 32
150000001450 anions Chemical class 0.000 description 31
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
239000002253 acid Substances 0.000 description 30
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 29
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
229910000104 sodium hydride Inorganic materials 0.000 description 26
239000005557 antagonist Substances 0.000 description 25
239000012279 sodium borohydride Substances 0.000 description 25
229910000033 sodium borohydride Inorganic materials 0.000 description 25
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
230000000694 effects Effects 0.000 description 23
230000035876 healing Effects 0.000 description 23
239000003921 oil Substances 0.000 description 23
235000019198 oils Nutrition 0.000 description 23
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 21
239000007864 aqueous solution Substances 0.000 description 21
241000700159 Rattus Species 0.000 description 19
239000003795 chemical substances by application Substances 0.000 description 19
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
230000011164 ossification Effects 0.000 description 18
238000010992 reflux Methods 0.000 description 17
VMKAFJQFKBASMU-QGZVFWFLSA-N (r)-2-methyl-cbs-oxazaborolidine Chemical compound C([C@@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-QGZVFWFLSA-N 0.000 description 16
239000012267 brine Substances 0.000 description 16
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 16
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
210000001519 tissue Anatomy 0.000 description 16
241000251539 Vertebrata <Metazoa> Species 0.000 description 15
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 15
210000004027 cell Anatomy 0.000 description 15
229910052943 magnesium sulfate Inorganic materials 0.000 description 15
235000019341 magnesium sulphate Nutrition 0.000 description 15
206010020649 Hyperkeratosis Diseases 0.000 description 14
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
239000003054 catalyst Substances 0.000 description 14
TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 14
150000004702 methyl esters Chemical class 0.000 description 14
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 14
238000004458 analytical method Methods 0.000 description 13
150000002148 esters Chemical class 0.000 description 13
125000006239 protecting group Chemical group 0.000 description 13
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
150000001732 carboxylic acid derivatives Chemical class 0.000 description 12
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 11
125000000524 functional group Chemical group 0.000 description 11
TYGXITCKYVKKFC-SNVBAGLBSA-N methyl 5-[3-[(2r)-2-formyl-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=O TYGXITCKYVKKFC-SNVBAGLBSA-N 0.000 description 11
239000000199 parathyroid hormone Substances 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
239000007858 starting material Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
239000002168 alkylating agent Substances 0.000 description 10
229940100198 alkylating agent Drugs 0.000 description 10
239000002585 base Substances 0.000 description 10
239000003085 diluting agent Substances 0.000 description 10
229940094443 oxytocics prostaglandins Drugs 0.000 description 10
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
102000003982 Parathyroid hormone Human genes 0.000 description 9
108090000445 Parathyroid hormone Proteins 0.000 description 9
102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
239000003638 chemical reducing agent Substances 0.000 description 9
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 9
238000005259 measurement Methods 0.000 description 9
229960001319 parathyroid hormone Drugs 0.000 description 9
239000002522 prostaglandin receptor stimulating agent Substances 0.000 description 9
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
239000000126 substance Substances 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 9
239000003039 volatile agent Substances 0.000 description 9
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 8
239000005711 Benzoic acid Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
229940124325 anabolic agent Drugs 0.000 description 8
239000003263 anabolic agent Substances 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 8
VFURZFXINHLLBT-GFCCVEGCSA-N ethyl 7-[(2r)-2-formyl-5-oxopyrrolidin-1-yl]heptanoate Chemical compound CCOC(=O)CCCCCCN1[C@@H](C=O)CCC1=O VFURZFXINHLLBT-GFCCVEGCSA-N 0.000 description 8
125000004494 ethyl ester group Chemical group 0.000 description 8
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
229910052500 inorganic mineral Inorganic materials 0.000 description 8
AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 8
235000010755 mineral Nutrition 0.000 description 8
239000011707 mineral Substances 0.000 description 8
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 8
238000012746 preparative thin layer chromatography Methods 0.000 description 8
IEZDOKQWPWZVQF-UHFFFAOYSA-N rolziracetam Chemical compound C1CC(=O)N2C(=O)CCC21 IEZDOKQWPWZVQF-UHFFFAOYSA-N 0.000 description 8
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 8
239000011775 sodium fluoride Substances 0.000 description 8
235000013024 sodium fluoride Nutrition 0.000 description 8
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 7
229940122361 Bisphosphonate Drugs 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
241000282412 Homo Species 0.000 description 7
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
150000001350 alkyl halides Chemical class 0.000 description 7
150000004663 bisphosphonates Chemical class 0.000 description 7
229960001701 chloroform Drugs 0.000 description 7
229960002986 dinoprostone Drugs 0.000 description 7
239000003324 growth hormone secretagogue Substances 0.000 description 7
230000036541 health Effects 0.000 description 7
238000005984 hydrogenation reaction Methods 0.000 description 7
230000008569 process Effects 0.000 description 7
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 7
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
102000008131 Bone Morphogenetic Protein 7 Human genes 0.000 description 6
108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
150000001298 alcohols Chemical class 0.000 description 6
150000001299 aldehydes Chemical class 0.000 description 6
150000008052 alkyl sulfonates Chemical class 0.000 description 6
230000000123 anti-resoprtive effect Effects 0.000 description 6
235000010233 benzoic acid Nutrition 0.000 description 6
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 6
239000000122 growth hormone Substances 0.000 description 6
239000010410 layer Substances 0.000 description 6
150000002825 nitriles Chemical class 0.000 description 6
230000008520 organization Effects 0.000 description 6
210000002997 osteoclast Anatomy 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
239000002243 precursor Substances 0.000 description 6
229940044601 receptor agonist Drugs 0.000 description 6
239000000018 receptor agonist Substances 0.000 description 6
239000011734 sodium Substances 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
210000002303 tibia Anatomy 0.000 description 6
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
TXZWDQOLYJCSFG-UHFFFAOYSA-N 5-[3-[tert-butyl(dimethyl)silyl]oxy-4-phenylbutyl]pyrrolidin-2-one Chemical compound C=1C=CC=CC=1CC(O[Si](C)(C)C(C)(C)C)CCC1CCC(=O)N1 TXZWDQOLYJCSFG-UHFFFAOYSA-N 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 5
102000018997 Growth Hormone Human genes 0.000 description 5
108010051696 Growth Hormone Proteins 0.000 description 5
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 5
206010020100 Hip fracture Diseases 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
150000001347 alkyl bromides Chemical class 0.000 description 5
150000001351 alkyl iodides Chemical class 0.000 description 5
239000000010 aprotic solvent Substances 0.000 description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
210000000845 cartilage Anatomy 0.000 description 5
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 5
201000010099 disease Diseases 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000001914 filtration Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
150000002576 ketones Chemical class 0.000 description 5
229960002378 oftasceine Drugs 0.000 description 5
239000000047 product Substances 0.000 description 5
239000000583 progesterone congener Substances 0.000 description 5
230000008929 regeneration Effects 0.000 description 5
238000011069 regeneration method Methods 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
150000003536 tetrazoles Chemical class 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
GLVJOHLPQHQJMH-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-naphthalen-2-ylpropan-2-one Chemical compound C1=CC=CC2=CC(CC(=O)CP(=O)(OC)OC)=CC=C21 GLVJOHLPQHQJMH-UHFFFAOYSA-N 0.000 description 4
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 4
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 4
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 4
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 4
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 4
241000557626 Corvus corax Species 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
230000001133 acceleration Effects 0.000 description 4
125000003158 alcohol group Chemical group 0.000 description 4
125000006241 alcohol protecting group Chemical group 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
235000019270 ammonium chloride Nutrition 0.000 description 4
150000001502 aryl halides Chemical class 0.000 description 4
229960005370 atorvastatin Drugs 0.000 description 4
238000005452 bending Methods 0.000 description 4
229940112869 bone morphogenetic protein Drugs 0.000 description 4
230000008416 bone turnover Effects 0.000 description 4
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 4
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
230000001054 cortical effect Effects 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
238000010511 deprotection reaction Methods 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
102000015694 estrogen receptors Human genes 0.000 description 4
108010038795 estrogen receptors Proteins 0.000 description 4
GSPWDJRYCQDGPO-UHFFFAOYSA-N ethyl 4-[2-[2-(3-hydroxy-4-phenylbutyl)-5-oxopyrrolidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1C(=O)CCC1CCC(O)CC1=CC=CC=C1 GSPWDJRYCQDGPO-UHFFFAOYSA-N 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
239000012634 fragment Substances 0.000 description 4
150000004820 halides Chemical class 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
125000004356 hydroxy functional group Chemical group O* 0.000 description 4
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
201000001881 impotence Diseases 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
KZRAAPTWXAMZHQ-UHFFFAOYSA-N methoxymethanamine Chemical compound COCN KZRAAPTWXAMZHQ-UHFFFAOYSA-N 0.000 description 4
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 4
229950009116 mevastatin Drugs 0.000 description 4
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 4
230000000399 orthopedic effect Effects 0.000 description 4
229910052763 palladium Inorganic materials 0.000 description 4
239000011574 phosphorus Substances 0.000 description 4
229910052698 phosphorus Inorganic materials 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
230000001737 promoting effect Effects 0.000 description 4
239000003586 protic polar solvent Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
239000012312 sodium hydride Substances 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
238000012289 standard assay Methods 0.000 description 4
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
229930192474 thiophene Natural products 0.000 description 4
210000000689 upper leg Anatomy 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
JORYTEOEUYNAJL-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-3-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=C2OCOC2=C1 JORYTEOEUYNAJL-UHFFFAOYSA-N 0.000 description 3
OZFANVREVNSDJM-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=CC(Cl)=C1 OZFANVREVNSDJM-UHFFFAOYSA-N 0.000 description 3
NAWVLGFYFTWPBE-UHFFFAOYSA-N 1-diethoxyphosphoryl-3-(4-fluoro-3-methylphenyl)propan-2-ol Chemical compound CCOP(=O)(OCC)CC(O)CC1=CC=C(F)C(C)=C1 NAWVLGFYFTWPBE-UHFFFAOYSA-N 0.000 description 3
RELPPYANIRFORI-UHFFFAOYSA-N 1-diethoxyphosphoryl-3-(4-fluoro-3-methylphenyl)propan-2-one Chemical compound CCOP(=O)(OCC)CC(=O)CC1=CC=C(F)C(C)=C1 RELPPYANIRFORI-UHFFFAOYSA-N 0.000 description 3
PJEWIHPAWTUFGD-UHFFFAOYSA-N 1-diethoxyphosphoryl-3-[3-(methoxymethyl)phenyl]propan-2-one Chemical compound CCOP(=O)(OCC)CC(=O)CC1=CC=CC(COC)=C1 PJEWIHPAWTUFGD-UHFFFAOYSA-N 0.000 description 3
KHKYLTTZTQTAGN-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-(3-phenylphenyl)propan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=CC(C=2C=CC=CC=2)=C1 KHKYLTTZTQTAGN-UHFFFAOYSA-N 0.000 description 3
QUBZTBJWGAIXDN-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-[3-(trifluoromethyl)phenyl]propan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=CC(C(F)(F)F)=C1 QUBZTBJWGAIXDN-UHFFFAOYSA-N 0.000 description 3
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 3
238000005160 1H NMR spectroscopy Methods 0.000 description 3
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 3
XDSWRPRZDAJWPU-BGERDNNASA-N 4-[3-[(2r)-2-[4-(1,3-benzodioxol-5-yl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl]propyl]benzoic acid Chemical compound C([C@@H]1C=CC(CC=2C=C3OCOC3=CC=2)O)CC(=O)N1CCCC1=CC=C(C(O)=O)C=C1 XDSWRPRZDAJWPU-BGERDNNASA-N 0.000 description 3
VYASUBHPACQVFC-UHFFFAOYSA-N 5-(3-hydroxy-4-phenylbutyl)pyrrolidin-2-one Chemical compound C=1C=CC=CC=1CC(O)CCC1CCC(=O)N1 VYASUBHPACQVFC-UHFFFAOYSA-N 0.000 description 3
WDXOZILVSFKBRL-UHFFFAOYSA-N 5-[3-hydroxy-4-(3-phenoxyphenyl)butyl]pyrrolidin-2-one Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1CC(O)CCC1CCC(=O)N1 WDXOZILVSFKBRL-UHFFFAOYSA-N 0.000 description 3
HAELTGKNMSJGAK-UHFFFAOYSA-N 5-[3-oxo-4-(3-phenoxyphenyl)butyl]pyrrolidin-2-one Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1CC(=O)CCC1CCC(=O)N1 HAELTGKNMSJGAK-UHFFFAOYSA-N 0.000 description 3
GNDPTVGVYYVVOT-UHFFFAOYSA-N 5-[4-(3-fluorophenyl)-3-oxobutyl]pyrrolidin-2-one Chemical compound FC1=CC=CC(CC(=O)CCC2NC(=O)CC2)=C1 GNDPTVGVYYVVOT-UHFFFAOYSA-N 0.000 description 3
HMNYAEMFCADHKL-UHFFFAOYSA-N 5-[4-(4-fluorophenyl)-3-oxobutyl]pyrrolidin-2-one Chemical compound C1=CC(F)=CC=C1CC(=O)CCC1NC(=O)CC1 HMNYAEMFCADHKL-UHFFFAOYSA-N 0.000 description 3
FRUMJWHHYIOBIT-LLVKDONJSA-N 7-[(2r)-2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]heptanenitrile Chemical compound OC[C@H]1CCC(=O)N1CCCCCCC#N FRUMJWHHYIOBIT-LLVKDONJSA-N 0.000 description 3
OUGXCQMOYWPHMR-LLVKDONJSA-N 7-[(2r)-2-formyl-5-oxopyrrolidin-1-yl]heptanenitrile Chemical compound O=C[C@H]1CCC(=O)N1CCCCCCC#N OUGXCQMOYWPHMR-LLVKDONJSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
102100033367 Appetite-regulating hormone Human genes 0.000 description 3
101710111255 Appetite-regulating hormone Proteins 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000006386 Bone Resorption Diseases 0.000 description 3
208000020084 Bone disease Diseases 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
206010057175 Mass conditions Diseases 0.000 description 3
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
108700020797 Parathyroid Hormone-Related Proteins 0.000 description 3
102000043299 Parathyroid hormone-related Human genes 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102100035842 Prostaglandin E2 receptor EP1 subtype Human genes 0.000 description 3
102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000002411 adverse Effects 0.000 description 3
230000032683 aging Effects 0.000 description 3
229940062527 alendronate Drugs 0.000 description 3
150000001335 aliphatic alkanes Chemical class 0.000 description 3
150000001348 alkyl chlorides Chemical class 0.000 description 3
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 3
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
230000001195 anabolic effect Effects 0.000 description 3
MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 3
238000003556 assay Methods 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
230000024279 bone resorption Effects 0.000 description 3
229940124630 bronchodilator Drugs 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
150000001733 carboxylic acid esters Chemical class 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 3
YLFBFPXKTIQSSY-UHFFFAOYSA-N dimethoxy(oxo)phosphanium Chemical compound CO[P+](=O)OC YLFBFPXKTIQSSY-UHFFFAOYSA-N 0.000 description 3
XXZLFVKASFCYEI-OAHLLOKOSA-N ethyl 2-[3-[(2R)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-oxopyrrolidin-1-yl]propyl]-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(CCCN2C(CC[C@@H]2CO[Si](C)(C)C(C)(C)C)=O)=N1 XXZLFVKASFCYEI-OAHLLOKOSA-N 0.000 description 3
CNHISCQPKKGDPO-UHFFFAOYSA-N ethyl 2-bromo-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(Br)=N1 CNHISCQPKKGDPO-UHFFFAOYSA-N 0.000 description 3
KPMNVWCCNVFESA-FQEVSTJZSA-N ethyl 7-[(2r)-2-[4-(3-bromophenyl)-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoate Chemical compound C1CC(=O)N(CCCCCCC(=O)OCC)[C@H]1C=CC(=O)CC1=CC=CC(Br)=C1 KPMNVWCCNVFESA-FQEVSTJZSA-N 0.000 description 3
230000001815 facial effect Effects 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
238000003304 gavage Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
150000004678 hydrides Chemical class 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
VKBCJIJGDJYNIP-UHFFFAOYSA-N methyl 2-(3-phenylphenyl)acetate Chemical compound COC(=O)CC1=CC=CC(C=2C=CC=CC=2)=C1 VKBCJIJGDJYNIP-UHFFFAOYSA-N 0.000 description 3
VMHPVAWXMHRICK-UHFFFAOYSA-N methyl 4-(3-bromopropyl)benzoate Chemical compound COC(=O)C1=CC=C(CCCBr)C=C1 VMHPVAWXMHRICK-UHFFFAOYSA-N 0.000 description 3
ARNGRGQYXABYAT-UHFFFAOYSA-N methyl 4-(3-hydroxypropyl)benzoate Chemical compound COC(=O)C1=CC=C(CCCO)C=C1 ARNGRGQYXABYAT-UHFFFAOYSA-N 0.000 description 3
CYMUETWUGMNGIO-UHFFFAOYSA-N n-methoxy-n-methyl-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound CON(C)C(=O)CC1=CC=CC(C(F)(F)F)=C1 CYMUETWUGMNGIO-UHFFFAOYSA-N 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 3
239000002089 prostaglandin antagonist Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
235000009518 sodium iodide Nutrition 0.000 description 3
230000003033 spasmogenic effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
150000003573 thiols Chemical class 0.000 description 3
239000011701 zinc Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
ZGGHKIMDNBDHJB-RPQBTBOMSA-M (3S,5R)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-RPQBTBOMSA-M 0.000 description 2
VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 2
HOBJEFOCIRXQKH-SCSAIBSYSA-N (5r)-5-(hydroxymethyl)pyrrolidin-2-one Chemical compound OC[C@H]1CCC(=O)N1 HOBJEFOCIRXQKH-SCSAIBSYSA-N 0.000 description 2
125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 2
HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
NYTJUSHDAHWGGT-UHFFFAOYSA-N 1-(3-bromophenyl)-3-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=CC(Br)=C1 NYTJUSHDAHWGGT-UHFFFAOYSA-N 0.000 description 2
IWQISEXIPZPFGG-UHFFFAOYSA-N 1-diethoxyphosphoryl-3-(4-ethylphenyl)propan-2-one Chemical compound CCOP(=O)(OCC)CC(=O)CC1=CC=C(CC)C=C1 IWQISEXIPZPFGG-UHFFFAOYSA-N 0.000 description 2
MUNPYKGLTLFKBE-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-(3-phenoxyphenyl)propan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=CC(OC=2C=CC=CC=2)=C1 MUNPYKGLTLFKBE-UHFFFAOYSA-N 0.000 description 2
FMEWANGHXVQRPI-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-[2-(trifluoromethyl)phenyl]propan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=CC=C1C(F)(F)F FMEWANGHXVQRPI-UHFFFAOYSA-N 0.000 description 2
RSEJVIDWZXYLGW-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-[3-(trifluoromethoxy)phenyl]propan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=CC(OC(F)(F)F)=C1 RSEJVIDWZXYLGW-UHFFFAOYSA-N 0.000 description 2
HQJAUSGLWRLGOI-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-phenylpropan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=CC=C1 HQJAUSGLWRLGOI-UHFFFAOYSA-N 0.000 description 2
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
BLJGQNWXHZMQOS-UHFFFAOYSA-N 2-(2-oxopyrrolidin-1-yl)heptanenitrile Chemical compound O=C1CCCN1C(C#N)CCCCC BLJGQNWXHZMQOS-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
HJQQVNIORAQATK-UHFFFAOYSA-N 3-[4-(1,2-diphenylbut-1-enyl)phenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C(CC)=C(C=1C=CC(C=CC(O)=O)=CC=1)C1=CC=CC=C1 HJQQVNIORAQATK-UHFFFAOYSA-N 0.000 description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 2
WGVTVAQXBSHSQR-UHFFFAOYSA-N 4-[3-[2-(3-hydroxy-4-phenylbutyl)-5-oxopyrrolidin-1-yl]propyl]benzonitrile Chemical compound C=1C=CC=CC=1CC(O)CCC1CCC(=O)N1CCCC1=CC=C(C#N)C=C1 WGVTVAQXBSHSQR-UHFFFAOYSA-N 0.000 description 2
FWKBHFGIJCTFGH-UHFFFAOYSA-N 4-[3-[2-[3-[tert-butyl(dimethyl)silyl]oxy-4-phenylbutyl]-5-oxopyrrolidin-1-yl]propyl]benzonitrile Chemical compound C=1C=CC=CC=1CC(O[Si](C)(C)C(C)(C)C)CCC1CCC(=O)N1CCCC1=CC=C(C#N)C=C1 FWKBHFGIJCTFGH-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
UOGUMNDDVPYVGT-UHFFFAOYSA-N 5-(3-bromo-3-hydroxybutyl)pyrrolidin-2-one Chemical compound CC(O)(Br)CCC1CCC(=O)N1 UOGUMNDDVPYVGT-UHFFFAOYSA-N 0.000 description 2
ZCBNQGIWWKNBCL-UHFFFAOYSA-N 5-(3-oxo-4-phenylbutyl)pyrrolidin-2-one Chemical compound C=1C=CC=CC=1CC(=O)CCC1CCC(=O)N1 ZCBNQGIWWKNBCL-UHFFFAOYSA-N 0.000 description 2
REKLGDRSMJUJBR-UHFFFAOYSA-N 5-[3-[tert-butyl(dimethyl)silyl]oxy-4-(3-phenoxyphenyl)butyl]pyrrolidin-2-one Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1CC(O[Si](C)(C)C(C)(C)C)CCC1CCC(=O)N1 REKLGDRSMJUJBR-UHFFFAOYSA-N 0.000 description 2
IRQGUQFUNOFPKQ-UHFFFAOYSA-N 5-[3-[tert-butyl(dimethyl)silyl]oxy-4-[3-(trifluoromethyl)phenyl]butyl]pyrrolidin-2-one Chemical compound C=1C=CC(C(F)(F)F)=CC=1CC(O[Si](C)(C)C(C)(C)C)CCC1CCC(=O)N1 IRQGUQFUNOFPKQ-UHFFFAOYSA-N 0.000 description 2
REMRSWNHASHECZ-UHFFFAOYSA-N 5-[3-oxo-4-[3-(trifluoromethyl)phenyl]butyl]pyrrolidin-2-one Chemical compound FC(F)(F)C1=CC=CC(CC(=O)CCC2NC(=O)CC2)=C1 REMRSWNHASHECZ-UHFFFAOYSA-N 0.000 description 2
OAWCFLDKGQNSLB-UHFFFAOYSA-N 5-[4-(3-chlorophenyl)-3-oxobutyl]pyrrolidin-2-one Chemical compound ClC1=CC=CC(CC(=O)CCC2NC(=O)CC2)=C1 OAWCFLDKGQNSLB-UHFFFAOYSA-N 0.000 description 2
OATMWXXAHKMXFU-UHFFFAOYSA-N 5-[4-(4-fluorophenyl)-3-hydroxybutyl]pyrrolidin-2-one Chemical compound C=1C=C(F)C=CC=1CC(O)CCC1CCC(=O)N1 OATMWXXAHKMXFU-UHFFFAOYSA-N 0.000 description 2
SSQLMQBZAPRIRS-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCN1CCCCC1 SSQLMQBZAPRIRS-UHFFFAOYSA-N 0.000 description 2
BFSBCWHQSDRJHT-QHCPKHFHSA-N 7-[(2r)-2-(4-naphthalen-2-yl-3-oxobut-1-enyl)-5-oxopyrrolidin-1-yl]heptanenitrile Chemical compound C=1C=C2C=CC=CC2=CC=1CC(=O)C=C[C@H]1CCC(=O)N1CCCCCCC#N BFSBCWHQSDRJHT-QHCPKHFHSA-N 0.000 description 2
VRQWHBXJTBXEBA-ZENAZSQFSA-N 7-[(2r)-2-[4-(1,3-benzodioxol-5-yl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid Chemical compound C=1C=C2OCOC2=CC=1CC(O)C=C[C@H]1CCC(=O)N1CCCCCCC(O)=O VRQWHBXJTBXEBA-ZENAZSQFSA-N 0.000 description 2
PDGDTFHFGWDBKI-NRFANRHFSA-N 7-[(2r)-2-[4-[3-(methoxymethyl)phenyl]-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]heptanenitrile Chemical compound COCC1=CC=CC(CC(=O)C=C[C@@H]2N(C(=O)CC2)CCCCCCC#N)=C1 PDGDTFHFGWDBKI-NRFANRHFSA-N 0.000 description 2
HVVQSKCGHAPHMV-UHFFFAOYSA-N 7-bromoheptanenitrile Chemical compound BrCCCCCCC#N HVVQSKCGHAPHMV-UHFFFAOYSA-N 0.000 description 2
241001589086 Bellapiscis medius Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
208000010228 Erectile Dysfunction Diseases 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
239000012448 Lithium borohydride Substances 0.000 description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
101150053131 PTGER3 gene Proteins 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
229940123028 Prostaglandin EP4 receptor agonist Drugs 0.000 description 2
102000015433 Prostaglandin Receptors Human genes 0.000 description 2
108010050183 Prostaglandin Receptors Proteins 0.000 description 2
CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical class O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 description 2
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
238000006069 Suzuki reaction reaction Methods 0.000 description 2
201000010814 Synostosis Diseases 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
208000002495 Uterine Neoplasms Diseases 0.000 description 2
NOXYEXFQXDRHTA-UHFFFAOYSA-N [O-2].[O-2].[O-2].[Cr+3].[Cr+3].C1=CC=NC=C1 Chemical compound [O-2].[O-2].[O-2].[Cr+3].[Cr+3].C1=CC=NC=C1 NOXYEXFQXDRHTA-UHFFFAOYSA-N 0.000 description 2
229940022663 acetate Drugs 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
230000003276 anti-hypertensive effect Effects 0.000 description 2
150000001499 aryl bromides Chemical class 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
239000007844 bleaching agent Substances 0.000 description 2
230000008468 bone growth Effects 0.000 description 2
230000010072 bone remodeling Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
230000003182 bronchodilatating effect Effects 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229960005110 cerivastatin Drugs 0.000 description 2
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
229960002286 clodronic acid Drugs 0.000 description 2
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000004891 communication Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
229950003040 dalvastatin Drugs 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001066 destructive effect Effects 0.000 description 2
229940043279 diisopropylamine Drugs 0.000 description 2
VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 2
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
229950004203 droloxifene Drugs 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
239000012039 electrophile Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000002745 epiphysis Anatomy 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
CAERSDJFKGMKLY-UHFFFAOYSA-N ethyl 2-(3-bromophenyl)acetate Chemical compound CCOC(=O)CC1=CC=CC(Br)=C1 CAERSDJFKGMKLY-UHFFFAOYSA-N 0.000 description 2
PEPILSVZOINLHW-SNVBAGLBSA-N ethyl 2-[3-[(2r)-2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]propyl]-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(CCCN2C(CC[C@@H]2CO)=O)=N1 PEPILSVZOINLHW-SNVBAGLBSA-N 0.000 description 2
CSTGNEZQERQUCM-UHFFFAOYSA-N ethyl 4-[2-[2-[3-[tert-butyl(dimethyl)silyl]oxy-4-phenylbutyl]-5-oxopyrrolidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1C(=O)CCC1CCC(O[Si](C)(C)C(C)(C)C)CC1=CC=CC=C1 CSTGNEZQERQUCM-UHFFFAOYSA-N 0.000 description 2
YDARFNBVDDWMBQ-GFCCVEGCSA-N ethyl 7-[(2r)-2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]heptanoate Chemical compound CCOC(=O)CCCCCCN1[C@@H](CO)CCC1=O YDARFNBVDDWMBQ-GFCCVEGCSA-N 0.000 description 2
GZHLKZARNGMNQT-XJDOXCRVSA-N ethyl 7-[(2r)-2-[4-(1,3-benzodioxol-5-yl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoate Chemical compound C1CC(=O)N(CCCCCCC(=O)OCC)[C@H]1C=CC(O)CC1=CC=C(OCO2)C2=C1 GZHLKZARNGMNQT-XJDOXCRVSA-N 0.000 description 2
VQVAHSZEAAVATH-QHCPKHFHSA-N ethyl 7-[(2r)-2-[4-[3-(2-methoxyethyl)phenyl]-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoate Chemical compound C1CC(=O)N(CCCCCCC(=O)OCC)[C@H]1C=CC(=O)CC1=CC=CC(CCOC)=C1 VQVAHSZEAAVATH-QHCPKHFHSA-N 0.000 description 2
QSFVVMNHHDLQCT-IBGZPJMESA-N ethyl 7-[(5r)-2-oxo-5-[3-oxo-4-[3-(trifluoromethoxy)phenyl]but-1-enyl]pyrrolidin-1-yl]heptanoate Chemical compound C1CC(=O)N(CCCCCCC(=O)OCC)[C@H]1C=CC(=O)CC1=CC=CC(OC(F)(F)F)=C1 QSFVVMNHHDLQCT-IBGZPJMESA-N 0.000 description 2
OOBFNDGMAGSNKA-UHFFFAOYSA-N ethyl 7-bromoheptanoate Chemical compound CCOC(=O)CCCCCCBr OOBFNDGMAGSNKA-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
210000002082 fibula Anatomy 0.000 description 2
229960003765 fluvastatin Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
150000004795 grignard reagents Chemical class 0.000 description 2
125000003106 haloaryl group Chemical group 0.000 description 2
229960005236 ibandronic acid Drugs 0.000 description 2
229950002248 idoxifene Drugs 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
229910001502 inorganic halide Inorganic materials 0.000 description 2
229910017053 inorganic salt Inorganic materials 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
229910003002 lithium salt Inorganic materials 0.000 description 2
159000000002 lithium salts Chemical class 0.000 description 2
230000007774 longterm Effects 0.000 description 2
229960004844 lovastatin Drugs 0.000 description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
210000001699 lower leg Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
QFLBWNWKBXCHKS-UHFFFAOYSA-N methyl 4-(3-hydroxyprop-1-ynyl)benzoate Chemical compound COC(=O)C1=CC=C(C#CCO)C=C1 QFLBWNWKBXCHKS-UHFFFAOYSA-N 0.000 description 2
PDYYOTSXOJGFNM-UHFFFAOYSA-N methyl 4-[3-[2-[3-[tert-butyl(dimethyl)silyl]oxy-4-phenylbutyl]-5-oxopyrrolidin-1-yl]propyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCCN1C(=O)CCC1CCC(O[Si](C)(C)C(C)(C)C)CC1=CC=CC=C1 PDYYOTSXOJGFNM-UHFFFAOYSA-N 0.000 description 2
VJWSUSVBKUEDJR-SFHVURJKSA-N methyl 5-[3-[(2r)-2-[4-(4-fluorophenyl)-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=C(F)C=C1 VJWSUSVBKUEDJR-SFHVURJKSA-N 0.000 description 2
ZIXWMVGUJNUFSF-OAHLLOKOSA-N methyl 5-[3-[(2r)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-oxopyrrolidin-1-yl]prop-1-ynyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1C#CCN1C(=O)CC[C@@H]1CO[Si](C)(C)C(C)(C)C ZIXWMVGUJNUFSF-OAHLLOKOSA-N 0.000 description 2
FSPSYONJMSWYIU-OAHLLOKOSA-N methyl 5-[3-[(2r)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1CO[Si](C)(C)C(C)(C)C FSPSYONJMSWYIU-OAHLLOKOSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
229910000510 noble metal Inorganic materials 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000001050 pharmacotherapy Methods 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
229910003446 platinum oxide Inorganic materials 0.000 description 2
238000013001 point bending Methods 0.000 description 2
208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
239000000843 powder Substances 0.000 description 2
229960002965 pravastatin Drugs 0.000 description 2
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
238000004237 preparative chromatography Methods 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
NRTYMEPCRDJMPZ-UHFFFAOYSA-N pyridine;2,2,2-trifluoroacetic acid Chemical compound C1=CC=NC=C1.OC(=O)C(F)(F)F NRTYMEPCRDJMPZ-UHFFFAOYSA-N 0.000 description 2
230000006340 racemization Effects 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
229960004622 raloxifene Drugs 0.000 description 2
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
DHNUAKOQUGJUGA-UHFFFAOYSA-N silicon;sulfane Chemical compound [Si].S DHNUAKOQUGJUGA-UHFFFAOYSA-N 0.000 description 2
229960002855 simvastatin Drugs 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000003068 static effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000005728 strengthening Methods 0.000 description 2
230000035882 stress Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
150000003871 sulfonates Chemical class 0.000 description 2
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229960001603 tamoxifen Drugs 0.000 description 2
238000003419 tautomerization reaction Methods 0.000 description 2
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
229960005026 toremifene Drugs 0.000 description 2
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
230000000304 vasodilatating effect Effects 0.000 description 2
229960004276 zoledronic acid Drugs 0.000 description 2
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
DLTWUXUDIFVVOM-OSFPVTNASA-N (3s,8r,9s,10r,11s,13s,14s,17r)-17-ethynyl-11,13-dimethyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound O[C@H]1CC[C@@H]2[C@H]3[C@@H](C)C[C@]4(C)[C@@](C#C)(O)CC[C@H]4[C@@H]3CCC2=C1 DLTWUXUDIFVVOM-OSFPVTNASA-N 0.000 description 1
HSYWFJBHXIUUCZ-XGXHKTLJSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-2,3,4,7,8,9,10,11,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ol Chemical compound C1CCC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC=C21 HSYWFJBHXIUUCZ-XGXHKTLJSA-N 0.000 description 1
DHOKBGHAEUVRMO-SLHNCBLASA-N (8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-2,3,4,6,7,8,9,11,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ol Chemical compound C1CCCC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 DHOKBGHAEUVRMO-SLHNCBLASA-N 0.000 description 1
KEOBKPHJNAILCW-FUMNGEBKSA-N (8s,13s,14s,17s)-17-(2-chloroethynyl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#CCl)CC3)C3=C21 KEOBKPHJNAILCW-FUMNGEBKSA-N 0.000 description 1
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
JWQYZECMEPOAPF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1=CC=C2CC(O)CCC2=C1 JWQYZECMEPOAPF-UHFFFAOYSA-N 0.000 description 1
YIPWQAHTCKALEO-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=C(Cl)C=C1 YIPWQAHTCKALEO-UHFFFAOYSA-N 0.000 description 1
XGASTRVQNVVYIZ-UHFFFAOYSA-N 1-(chloromethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CCl)=C1 XGASTRVQNVVYIZ-UHFFFAOYSA-N 0.000 description 1
QUYVTGFWFHQVRO-UHFFFAOYSA-N 1-(chloromethyl)-3-phenoxybenzene Chemical compound ClCC1=CC=CC(OC=2C=CC=CC=2)=C1 QUYVTGFWFHQVRO-UHFFFAOYSA-N 0.000 description 1
PJEXUIKBGBSHBS-UHFFFAOYSA-N 1-(hydroxymethyl)pyrrolidin-2-one Chemical compound OCN1CCCC1=O PJEXUIKBGBSHBS-UHFFFAOYSA-N 0.000 description 1
ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
USYQKCQEVBFJRP-UHFFFAOYSA-N 1-bromo-3-phenylbenzene Chemical group BrC1=CC=CC(C=2C=CC=CC=2)=C1 USYQKCQEVBFJRP-UHFFFAOYSA-N 0.000 description 1
OILPPNKWYFAORW-UHFFFAOYSA-N 1-cyclohexyl-3-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1CCCCC1 OILPPNKWYFAORW-UHFFFAOYSA-N 0.000 description 1
UFETWGZWAUALTN-UHFFFAOYSA-N 1-diethoxyphosphoryl-3-[3-(2-methoxyethyl)phenyl]propan-2-one Chemical compound CCOP(=O)(OCC)CC(=O)CC1=CC=CC(CCOC)=C1 UFETWGZWAUALTN-UHFFFAOYSA-N 0.000 description 1
HTTUPTMZPOGKEB-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-(3-fluorophenyl)propan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=CC(F)=C1 HTTUPTMZPOGKEB-UHFFFAOYSA-N 0.000 description 1
QNOXQOMRJZRWQU-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-(4-fluorophenyl)propan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1=CC=C(F)C=C1 QNOXQOMRJZRWQU-UHFFFAOYSA-N 0.000 description 1
ONQBOTKLCMXPOF-UHFFFAOYSA-N 1-ethylpyrrolidine Chemical compound CCN1CCCC1 ONQBOTKLCMXPOF-UHFFFAOYSA-N 0.000 description 1
108020004463 18S ribosomal RNA Proteins 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
JMJKWWPXPGFVBE-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydro-1h-isoquinolin-6-ol Chemical compound C1CC2=CC(O)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)N1C1=CC=C(F)C=C1 JMJKWWPXPGFVBE-UHFFFAOYSA-N 0.000 description 1
FUKXIMRHLZJUCG-UHFFFAOYSA-N 2-(diethoxyphosphorylmethyl)oxirane Chemical compound CCOP(=O)(OCC)CC1CO1 FUKXIMRHLZJUCG-UHFFFAOYSA-N 0.000 description 1
BLXXCCIBGGBDHI-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1 BLXXCCIBGGBDHI-UHFFFAOYSA-N 0.000 description 1
UMUPQWIGCOZEOY-JOCHJYFZSA-N 2-amino-2-methyl-n-[(2r)-1-(1-methylsulfonylspiro[2h-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)OCC1=CC=CC=C1 UMUPQWIGCOZEOY-JOCHJYFZSA-N 0.000 description 1
LXGKQHLPERZZTF-UHFFFAOYSA-N 2-bromo-3h-thiophene-2-carboxylic acid Chemical compound OC(=O)C1(Br)CC=CS1 LXGKQHLPERZZTF-UHFFFAOYSA-N 0.000 description 1
HMBSMLATJKWAHH-UHFFFAOYSA-N 2-phenyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydro-1h-isoquinolin-6-ol Chemical compound C1CC2=CC(O)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)N1C1=CC=CC=C1 HMBSMLATJKWAHH-UHFFFAOYSA-N 0.000 description 1
NEAHTABRXFKZGG-UHFFFAOYSA-N 2-pyridin-4-yl-3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=CC(C=2NC3=CN=CC=C3N=2)=C1 NEAHTABRXFKZGG-UHFFFAOYSA-N 0.000 description 1
AFNUHOACSSFYTH-UHFFFAOYSA-N 3-propylthiophene-2-carboxylic acid Chemical compound CCCC=1C=CSC=1C(O)=O AFNUHOACSSFYTH-UHFFFAOYSA-N 0.000 description 1
GSQHPAQTFSHMPZ-UHFFFAOYSA-N 4-(3-bromopropyl)benzonitrile Chemical compound BrCCCC1=CC=C(C#N)C=C1 GSQHPAQTFSHMPZ-UHFFFAOYSA-N 0.000 description 1
UHOZTWTXLKNTAE-UHFFFAOYSA-N 4-[2-[2-(3-hydroxy-4-phenylbutyl)-5-oxopyrrolidin-1-yl]ethoxy]benzoic acid Chemical compound C=1C=CC=CC=1CC(O)CCC1CCC(=O)N1CCOC1=CC=C(C(O)=O)C=C1 UHOZTWTXLKNTAE-UHFFFAOYSA-N 0.000 description 1
DQLDMXGXNPDHDY-UHFFFAOYSA-N 4-[3-[2-(3-hydroxy-4-phenylbutyl)-5-oxopyrrolidin-1-yl]propyl]benzoic acid Chemical compound C=1C=CC=CC=1CC(O)CCC1CCC(=O)N1CCCC1=CC=C(C(O)=O)C=C1 DQLDMXGXNPDHDY-UHFFFAOYSA-N 0.000 description 1
SDEZJSYVFCHZOB-UHFFFAOYSA-N 4-[3-[2-[3-hydroxy-4-(3-phenoxyphenyl)butyl]-5-oxopyrrolidin-1-yl]propyl]benzoic acid Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1CC(O)CCC1CCC(=O)N1CCCC1=CC=C(C(O)=O)C=C1 SDEZJSYVFCHZOB-UHFFFAOYSA-N 0.000 description 1
SRSAPNTYWCSITR-UHFFFAOYSA-N 4-[3-[2-[3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]-5-oxopyrrolidin-1-yl]propyl]benzoic acid Chemical compound C=1C=CC(C(F)(F)F)=CC=1CC(O)CCC1CCC(=O)N1CCCC1=CC=C(C(O)=O)C=C1 SRSAPNTYWCSITR-UHFFFAOYSA-N 0.000 description 1
APXHYSJSTXRVDF-UHFFFAOYSA-N 4-[3-[2-[4-(3-chlorophenyl)-3-hydroxybutyl]-5-oxopyrrolidin-1-yl]propyl]benzoic acid Chemical compound C=1C=CC(Cl)=CC=1CC(O)CCC1CCC(=O)N1CCCC1=CC=C(C(O)=O)C=C1 APXHYSJSTXRVDF-UHFFFAOYSA-N 0.000 description 1
CILMWGKYOULOMR-UHFFFAOYSA-N 4-[3-[2-[4-(3-fluorophenyl)-3-hydroxybutyl]-5-oxopyrrolidin-1-yl]propyl]benzoic acid Chemical compound C=1C=CC(F)=CC=1CC(O)CCC1CCC(=O)N1CCCC1=CC=C(C(O)=O)C=C1 CILMWGKYOULOMR-UHFFFAOYSA-N 0.000 description 1
ZSPAEDJDADQTKU-UHFFFAOYSA-N 4-[3-[2-[4-(4-fluorophenyl)-3-hydroxybutyl]-5-oxopyrrolidin-1-yl]propyl]benzoic acid Chemical compound C=1C=C(F)C=CC=1CC(O)CCC1CCC(=O)N1CCCC1=CC=C(C(O)=O)C=C1 ZSPAEDJDADQTKU-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
OONCJGGGPWDKEE-KRWDZBQOSA-N 5-[3-[(2R)-2-[4-(3-fluorophenyl)-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylic acid Chemical compound FC=1C=C(C=CC=1)CC(C=C[C@@H]1N(C(CC1)=O)CCCC1=CC=C(S1)C(=O)O)=O OONCJGGGPWDKEE-KRWDZBQOSA-N 0.000 description 1
IKVNIPLVFNKSRX-KRWDZBQOSA-N 5-[3-[(5R)-2-oxo-5-(3-oxo-4-phenylbut-1-enyl)pyrrolidin-1-yl]propyl]thiophene-2-carboxylic acid Chemical compound O=C1N([C@H](CC1)C=CC(CC1=CC=CC=C1)=O)CCCC1=CC=C(S1)C(=O)O IKVNIPLVFNKSRX-KRWDZBQOSA-N 0.000 description 1
ZZBMOSXMXZEBIV-UHFFFAOYSA-N 5-[3-[tert-butyl(dimethyl)silyl]oxy-4-(3-chlorophenyl)butyl]pyrrolidin-2-one Chemical compound C=1C=CC(Cl)=CC=1CC(O[Si](C)(C)C(C)(C)C)CCC1CCC(=O)N1 ZZBMOSXMXZEBIV-UHFFFAOYSA-N 0.000 description 1
NNKQTVQXEWLWJP-UHFFFAOYSA-N 5-[3-[tert-butyl(dimethyl)silyl]oxy-4-(3-fluorophenyl)butyl]pyrrolidin-2-one Chemical compound C=1C=CC(F)=CC=1CC(O[Si](C)(C)C(C)(C)C)CCC1CCC(=O)N1 NNKQTVQXEWLWJP-UHFFFAOYSA-N 0.000 description 1
HVGRUOYWJYOTDJ-UHFFFAOYSA-N 5-[3-[tert-butyl(dimethyl)silyl]oxy-4-(4-fluorophenyl)butyl]pyrrolidin-2-one Chemical compound C=1C=C(F)C=CC=1CC(O[Si](C)(C)C(C)(C)C)CCC1CCC(=O)N1 HVGRUOYWJYOTDJ-UHFFFAOYSA-N 0.000 description 1
VHWUOYZRNSJTEG-UHFFFAOYSA-N 5-[3-bromo-3-[tert-butyl(dimethyl)silyl]oxybutyl]pyrrolidin-2-one Chemical compound CC(C)(C)[Si](C)(C)OC(C)(Br)CCC1CCC(=O)N1 VHWUOYZRNSJTEG-UHFFFAOYSA-N 0.000 description 1
RSMJOBRJNFOERO-UHFFFAOYSA-N 5-[3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]pyrrolidin-2-one Chemical compound C=1C=CC(C(F)(F)F)=CC=1CC(O)CCC1CCC(=O)N1 RSMJOBRJNFOERO-UHFFFAOYSA-N 0.000 description 1
FZCUPEHZVHFFEK-UHFFFAOYSA-N 5-[4-(3-chlorophenyl)-3-hydroxybutyl]pyrrolidin-2-one Chemical compound C=1C=CC(Cl)=CC=1CC(O)CCC1CCC(=O)N1 FZCUPEHZVHFFEK-UHFFFAOYSA-N 0.000 description 1
YTRBMRZOSVXYNE-UHFFFAOYSA-N 5-[4-(3-fluorophenyl)-3-hydroxybutyl]pyrrolidin-2-one Chemical compound C=1C=CC(F)=CC=1CC(O)CCC1CCC(=O)N1 YTRBMRZOSVXYNE-UHFFFAOYSA-N 0.000 description 1
XZJHMLFAEMPMGH-WTQRLHSKSA-N 7-[(2r)-2-(3-hydroxy-4-naphthalen-2-ylbutyl)-5-oxopyrrolidin-1-yl]heptanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1CC(O)CC[C@@H]1CCC(=O)N1CCCCCCC(O)=O XZJHMLFAEMPMGH-WTQRLHSKSA-N 0.000 description 1
PPVVRGQUTZDTFU-NQCNTLBGSA-N 7-[(2r)-2-[3-hydroxy-4-(3-phenoxyphenyl)but-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid Chemical compound C([C@@H]1N(C(=O)CC1)CCCCCCC(O)=O)=CC(O)CC(C=1)=CC=CC=1OC1=CC=CC=C1 PPVVRGQUTZDTFU-NQCNTLBGSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
VWAUPFMBXBWEQY-ANULTFPQSA-N Altrenogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC=C)C=C3)C3=C21 VWAUPFMBXBWEQY-ANULTFPQSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000605059 Bacteroidetes Species 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
101000692466 Bos taurus Prostaglandin F synthase 2 Proteins 0.000 description 1
206010006298 Breast pain Diseases 0.000 description 1
FUMYXQDHMTWYSY-IKOFQBKESA-N C(C)OC(CCCCCCN1[C@@H](CCC1=O)CCC(CC1=CC(=CC=C1)OC1=CC=CC=C1)O)=O Chemical compound C(C)OC(CCCCCCN1[C@@H](CCC1=O)CCC(CC1=CC(=CC=C1)OC1=CC=CC=C1)O)=O FUMYXQDHMTWYSY-IKOFQBKESA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000003044 Closed Fractures Diseases 0.000 description 1
241000043587 Collimonas fungivorans Species 0.000 description 1
208000034657 Convalescence Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
241000776471 DPANN group Species 0.000 description 1
229920004934 Dacron® Polymers 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007818 Grignard reagent Substances 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
238000006809 Jones oxidation reaction Methods 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
208000006662 Mastodynia Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
PGBFYLVIMDQYMS-UHFFFAOYSA-N Methyl thiophene-2-carboxylate Chemical compound COC(=O)C1=CC=CS1 PGBFYLVIMDQYMS-UHFFFAOYSA-N 0.000 description 1
PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
BUIQRTDBPCHRIR-UHFFFAOYSA-L O[Cr](Cl)(=O)=O Chemical compound O[Cr](Cl)(=O)=O BUIQRTDBPCHRIR-UHFFFAOYSA-L 0.000 description 1
DFZKYPXUXWIBHF-UHFFFAOYSA-N Oc1ccc2CN(CCc2c1)c1ccc(F)cc1 Chemical compound Oc1ccc2CN(CCc2c1)c1ccc(F)cc1 DFZKYPXUXWIBHF-UHFFFAOYSA-N 0.000 description 1
239000012124 Opti-MEM Substances 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
101710195838 Prostaglandin E2 receptor EP4 subtype Proteins 0.000 description 1
229940127473 Prostaglandin Receptor Agonists Drugs 0.000 description 1
101150058615 Ptger1 gene Proteins 0.000 description 1
239000003391 RNA probe Substances 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
208000000875 Spinal Curvatures Diseases 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
238000006859 Swern oxidation reaction Methods 0.000 description 1
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
206010048049 Wrist fracture Diseases 0.000 description 1
DOYNWQALDMKHDH-UHFFFAOYSA-N [(2-hydroxyethylamino)-phosphonomethyl]phosphonic acid Chemical compound OCCNC(P(O)(O)=O)P(O)(O)=O DOYNWQALDMKHDH-UHFFFAOYSA-N 0.000 description 1
KSCZWFXQKITHSL-OKCNGXCSSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6-chloro-10,13-dimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1C[C@]2(C)[C@](C(C)=O)(OC(C)=O)CC[C@H]2[C@@H]2C=C(Cl)C3=C[C@@H](OC(=O)C)CC[C@]3(C)[C@H]21 KSCZWFXQKITHSL-OKCNGXCSSA-N 0.000 description 1
WWSKHPDYSWDMNC-YRNSVOBJSA-N [(8r,9s,10r,13s,14s,16r,17r)-17-acetyl-6-chloro-10,13,16-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(C)=O)(OC(C)=O)[C@@]1(C)CC2 WWSKHPDYSWDMNC-YRNSVOBJSA-N 0.000 description 1
PSJMYDLEWUWIAN-KYPKCDLESA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-6-chloro-13-methyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 PSJMYDLEWUWIAN-KYPKCDLESA-N 0.000 description 1
XVNZXEWQQDCZSM-UHFFFAOYSA-N [anilino(phosphono)methyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1=CC=CC=C1 XVNZXEWQQDCZSM-UHFFFAOYSA-N 0.000 description 1
BFDMEODWJJUORJ-UHFFFAOYSA-N [dimethylamino(phosphono)methyl]phosphonic acid Chemical compound CN(C)C(P(O)(O)=O)P(O)(O)=O BFDMEODWJJUORJ-UHFFFAOYSA-N 0.000 description 1
229940022682 acetone Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
229960004343 alendronic acid Drugs 0.000 description 1
AHBKIEXBQNRDNL-FVCOMRFXSA-N algestone acetophenide Chemical compound C1([C@@]2(C)O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(CC[C@@H]3[C@@]4(C)CCC(=O)C=C4CC[C@H]32)C)C(=O)C)=CC=CC=C1 AHBKIEXBQNRDNL-FVCOMRFXSA-N 0.000 description 1
229950006673 algestone acetophenide Drugs 0.000 description 1
150000001334 alicyclic compounds Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960000971 altrenogest Drugs 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
KDLNOQQQEBKBQM-DICPTYMLSA-N anagestone acetate Chemical compound C([C@@]12C)CCC=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 KDLNOQQQEBKBQM-DICPTYMLSA-N 0.000 description 1
229950002552 anagestone acetate Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000001543 aryl boronic acids Chemical class 0.000 description 1
KZNCFIIFMFCSHL-UHFFFAOYSA-N benzyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)NC(C)C(=O)OCC1=CC=CC=C1 KZNCFIIFMFCSHL-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000002639 bone cement Substances 0.000 description 1
239000002617 bone density conservation agent Substances 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
MXOSTENCGSDMRE-UHFFFAOYSA-N butyl-chloro-dimethylsilane Chemical compound CCCC[Si](C)(C)Cl MXOSTENCGSDMRE-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
229950000136 cingestol Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
210000005257 cortical tissue Anatomy 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
150000001940 cyclopentanes Chemical class 0.000 description 1
BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical class O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 1
230000002950 deficient Effects 0.000 description 1
CGBCCZZJVKUAMX-DFXBJWIESA-N delmadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 CGBCCZZJVKUAMX-DFXBJWIESA-N 0.000 description 1
229950006075 delmadinone acetate Drugs 0.000 description 1
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
229960004976 desogestrel Drugs 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
150000001987 diarylethers Chemical class 0.000 description 1
238000011917 diastereoselective reduction Methods 0.000 description 1
RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
229910000071 diazene Inorganic materials 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
SKUHWSDHMJMHIW-UHFFFAOYSA-L disodium;[(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate Chemical group [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)SC1=CC=C(Cl)C=C1 SKUHWSDHMJMHIW-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
229960004913 dydrogesterone Drugs 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
238000009164 estrogen replacement therapy Methods 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
PAZCPTKXMNCXSJ-SNVBAGLBSA-N ethyl 2-[3-[(2r)-2-formyl-5-oxopyrrolidin-1-yl]propyl]-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(CCCN2C(CC[C@@H]2C=O)=O)=N1 PAZCPTKXMNCXSJ-SNVBAGLBSA-N 0.000 description 1
XHFUVBWCMLLKOZ-UHFFFAOYSA-N ethyl 2-amino-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(N)=N1 XHFUVBWCMLLKOZ-UHFFFAOYSA-N 0.000 description 1
KTYIFXLNIMPSKI-UHFFFAOYSA-N ethyl 2-bromo-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Br)S1 KTYIFXLNIMPSKI-UHFFFAOYSA-N 0.000 description 1
DBSADESEDBCPFO-UHFFFAOYSA-N ethyl 2-cyclopentylacetate Chemical compound CCOC(=O)CC1CCCC1 DBSADESEDBCPFO-UHFFFAOYSA-N 0.000 description 1
FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
BZLVOUTZDHRJPD-UHFFFAOYSA-N ethyl 4-(2-bromoethoxy)benzoate Chemical compound CCOC(=O)C1=CC=C(OCCBr)C=C1 BZLVOUTZDHRJPD-UHFFFAOYSA-N 0.000 description 1
XZIAFENWXIQIKR-UHFFFAOYSA-N ethyl 4-bromobenzoate Chemical compound CCOC(=O)C1=CC=C(Br)C=C1 XZIAFENWXIQIKR-UHFFFAOYSA-N 0.000 description 1
PZNHMXAOMDQLLE-UHFFFAOYSA-N ethyl 5-bromothiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(Br)S1 PZNHMXAOMDQLLE-UHFFFAOYSA-N 0.000 description 1
APOGYIHHBJVWJH-DEOSSOPVSA-N ethyl 7-[(2r)-2-(4-naphthalen-2-yl-3-oxobut-1-enyl)-5-oxopyrrolidin-1-yl]heptanoate Chemical compound C1CC(=O)N(CCCCCCC(=O)OCC)[C@H]1C=CC(=O)CC1=CC=C(C=CC=C2)C2=C1 APOGYIHHBJVWJH-DEOSSOPVSA-N 0.000 description 1
ZUIUNCHCMZGGNP-SKCDSABHSA-N ethyl 7-[(2r)-2-[3-hydroxy-4-(3-phenoxyphenyl)but-1-enyl]-5-oxopyrrolidin-1-yl]heptanoate Chemical compound C1CC(=O)N(CCCCCCC(=O)OCC)[C@H]1C=CC(O)CC1=CC=CC(OC=2C=CC=CC=2)=C1 ZUIUNCHCMZGGNP-SKCDSABHSA-N 0.000 description 1
GDSUNVOMWSEIKH-IBGZPJMESA-N ethyl 7-[(2r)-2-[4-(1,3-benzodioxol-5-yl)-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoate Chemical compound C1CC(=O)N(CCCCCCC(=O)OCC)[C@H]1C=CC(=O)CC1=CC=C(OCO2)C2=C1 GDSUNVOMWSEIKH-IBGZPJMESA-N 0.000 description 1
SRNNZHJXCPFTTJ-QFIPXVFZSA-N ethyl 7-[(2r)-2-[4-[3-(methoxymethyl)phenyl]-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoate Chemical compound C1CC(=O)N(CCCCCCC(=O)OCC)[C@H]1C=CC(=O)CC1=CC=CC(COC)=C1 SRNNZHJXCPFTTJ-QFIPXVFZSA-N 0.000 description 1
QPHHYDVJIUJKPG-DEOSSOPVSA-N ethyl 7-[(5r)-2-oxo-5-[3-oxo-4-(3-phenoxyphenyl)but-1-enyl]pyrrolidin-1-yl]heptanoate Chemical compound C1CC(=O)N(CCCCCCC(=O)OCC)[C@H]1C=CC(=O)CC1=CC=CC(OC=2C=CC=CC=2)=C1 QPHHYDVJIUJKPG-DEOSSOPVSA-N 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
229950007424 ethynerone Drugs 0.000 description 1
JYILPERKVHXLNF-QMNUTNMBSA-N ethynodiol Chemical compound O[C@H]1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 JYILPERKVHXLNF-QMNUTNMBSA-N 0.000 description 1
229960004585 etidronic acid Drugs 0.000 description 1
GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
229960002941 etonogestrel Drugs 0.000 description 1
229960000218 etynodiol Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
229950002886 haloprogesterone Drugs 0.000 description 1
GCCIFDUTISMRTG-TUPTUZDRSA-N haloprogesterone Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C(=O)C)(Br)[C@@]2(C)CC1 GCCIFDUTISMRTG-TUPTUZDRSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
SDAXRHHPNYTELL-UHFFFAOYSA-N heptanenitrile Chemical compound CCCCCCC#N SDAXRHHPNYTELL-UHFFFAOYSA-N 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
229910000043 hydrogen iodide Inorganic materials 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
150000004806 hydroxypyridines Chemical class 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229940047889 isobutyramide Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960002367 lasofoxifene Drugs 0.000 description 1
229960004400 levonorgestrel Drugs 0.000 description 1
XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 1
229950002728 levormeloxifene Drugs 0.000 description 1
229940002661 lipitor Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229960001910 lynestrenol Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
BQNQIHYLDYHYQP-UHFFFAOYSA-M magnesium;1-chloro-3-methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC(Cl)=C1 BQNQIHYLDYHYQP-UHFFFAOYSA-M 0.000 description 1
KZGFEBLGGYOPML-UHFFFAOYSA-M magnesium;1-fluoro-3-methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC(F)=C1 KZGFEBLGGYOPML-UHFFFAOYSA-M 0.000 description 1
JHMNJUQVLPODJN-UHFFFAOYSA-M magnesium;1-fluoro-4-methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=C(F)C=C1 JHMNJUQVLPODJN-UHFFFAOYSA-M 0.000 description 1
SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 1
229960000606 medrogestone Drugs 0.000 description 1
MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
229960003846 melengestrol acetate Drugs 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
ULSSGHADTSRELG-UHFFFAOYSA-N methyl 2-(3-bromophenyl)acetate Chemical compound COC(=O)CC1=CC=CC(Br)=C1 ULSSGHADTSRELG-UHFFFAOYSA-N 0.000 description 1
HTBBVKFFDDQVER-UHFFFAOYSA-N methyl 2-(3-chlorophenyl)acetate Chemical compound COC(=O)CC1=CC=CC(Cl)=C1 HTBBVKFFDDQVER-UHFFFAOYSA-N 0.000 description 1
OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
SSBHXDDGZAQNCH-HMTLIYDFSA-N methyl 4-[3-[(2r)-2-[4-(1,3-benzodioxol-5-yl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl]propyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(O)CC1=CC=C(OCO2)C2=C1 SSBHXDDGZAQNCH-HMTLIYDFSA-N 0.000 description 1
GENAXNGYOZJZJY-NRFANRHFSA-N methyl 4-[3-[(2r)-2-[4-(1,3-benzodioxol-5-yl)-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]propyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=C(OCO2)C2=C1 GENAXNGYOZJZJY-NRFANRHFSA-N 0.000 description 1
BPHNMVWUWRHHOZ-CQSZACIVSA-N methyl 4-[3-[(2r)-2-formyl-5-oxopyrrolidin-1-yl]propyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=O BPHNMVWUWRHHOZ-CQSZACIVSA-N 0.000 description 1
PRRBXZOTQDDOFR-UHFFFAOYSA-N methyl 4-[3-[2-(3-hydroxy-4-phenylbutyl)-5-oxopyrrolidin-1-yl]propyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCCN1C(=O)CCC1CCC(O)CC1=CC=CC=C1 PRRBXZOTQDDOFR-UHFFFAOYSA-N 0.000 description 1
DYUWQWMXZHDZOR-UHFFFAOYSA-N methyl 4-iodobenzoate Chemical compound COC(=O)C1=CC=C(I)C=C1 DYUWQWMXZHDZOR-UHFFFAOYSA-N 0.000 description 1
MGBXTCJYKMJGCS-SNVBAGLBSA-N methyl 5-[3-[(2r)-2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1CO MGBXTCJYKMJGCS-SNVBAGLBSA-N 0.000 description 1
LBISABYSBNAOHO-SFHVURJKSA-N methyl 5-[3-[(2r)-2-[4-(3-chlorophenyl)-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=CC(Cl)=C1 LBISABYSBNAOHO-SFHVURJKSA-N 0.000 description 1
IPZKLECZSIHAFM-SFHVURJKSA-N methyl 5-[3-[(2r)-2-[4-(3-fluorophenyl)-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=CC(F)=C1 IPZKLECZSIHAFM-SFHVURJKSA-N 0.000 description 1
ICXPKOBEJSYAMN-SFHVURJKSA-N methyl 5-[3-[(2r)-2-[4-(4-chlorophenyl)-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=C(Cl)C=C1 ICXPKOBEJSYAMN-SFHVURJKSA-N 0.000 description 1
VUJBVOPPOJVVTG-SFHVURJKSA-N methyl 5-[3-[(2r)-2-[4-(4-fluoro-3-methylphenyl)-3-oxobut-1-enyl]-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=C(F)C(C)=C1 VUJBVOPPOJVVTG-SFHVURJKSA-N 0.000 description 1
ZEMUOVVDZVEIKH-SFHVURJKSA-N methyl 5-[3-[(5r)-2-oxo-5-(3-oxo-4-phenylbut-1-enyl)pyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=CC=C1 ZEMUOVVDZVEIKH-SFHVURJKSA-N 0.000 description 1
MGWIFQZFPLGPJQ-KRWDZBQOSA-N methyl 5-[3-[(5r)-2-oxo-5-[3-oxo-4-[2-(trifluoromethyl)phenyl]but-1-enyl]pyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=CC=C1C(F)(F)F MGWIFQZFPLGPJQ-KRWDZBQOSA-N 0.000 description 1
AWJFNOGSZPVOFP-SFHVURJKSA-N methyl 5-[3-[(5r)-2-oxo-5-[3-oxo-4-[3-(trifluoromethyl)phenyl]but-1-enyl]pyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=CC(C(F)(F)F)=C1 AWJFNOGSZPVOFP-SFHVURJKSA-N 0.000 description 1
QLWUHAQCKDHUNL-UHFFFAOYSA-N methyl 5-bromothiophene-2-carboxylate Chemical compound COC(=O)C1=CC=C(Br)S1 QLWUHAQCKDHUNL-UHFFFAOYSA-N 0.000 description 1
GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
229950010804 metynodiol Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
UHAAFJWANJYDIS-UHFFFAOYSA-N n,n'-diethylmethanediimine Chemical compound CCN=C=NCC UHAAFJWANJYDIS-UHFFFAOYSA-N 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
229940053934 norethindrone Drugs 0.000 description 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
229960001858 norethynodrel Drugs 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000009806 oophorectomy Methods 0.000 description 1
238000011474 orchiectomy Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 1
229960003327 ormeloxifene Drugs 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000004072 osteoblast differentiation Effects 0.000 description 1
230000002642 osteogeneic effect Effects 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
229960003978 pamidronic acid Drugs 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000004560 pineal gland Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000005020 polyethylene terephthalate Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229940063238 premarin Drugs 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
UOCCVDMCNJYVIW-UHFFFAOYSA-N prop-2-yne-1-sulfonic acid Chemical class OS(=O)(=O)CC#C UOCCVDMCNJYVIW-UHFFFAOYSA-N 0.000 description 1
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
239000001294 propane Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000010926 purge Methods 0.000 description 1
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000002601 radiography Methods 0.000 description 1
229960002119 raloxifene hydrochloride Drugs 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
229960000759 risedronic acid Drugs 0.000 description 1
239000000565 sealant Substances 0.000 description 1
150000003333 secondary alcohols Chemical class 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000009958 sewing Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
FNXKBSAUKFCXIK-UHFFFAOYSA-M sodium;hydrogen carbonate;8-hydroxy-7-iodoquinoline-5-sulfonic acid Chemical class [Na+].OC([O-])=O.C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 FNXKBSAUKFCXIK-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
206010041569 spinal fracture Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000011916 stereoselective reduction Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
229960003454 tamoxifen citrate Drugs 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
QHBINVDUJXFESZ-DEOSSOPVSA-N tert-butyl 5-[3-[(2r)-2-(4-naphthalen-2-yl-3-oxobut-1-enyl)-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC(C)(C)C)=CC=C1CCCN1C(=O)CC[C@@H]1C=CC(=O)CC1=CC=C(C=CC=C2)C2=C1 QHBINVDUJXFESZ-DEOSSOPVSA-N 0.000 description 1
SZHIVWSUCCSBNX-GFCCVEGCSA-N tert-butyl 5-[3-[(2r)-2-formyl-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC(C)(C)C)=CC=C1CCCN1C(=O)CC[C@@H]1C=O SZHIVWSUCCSBNX-GFCCVEGCSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 1
238000010998 test method Methods 0.000 description 1
125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
229950004815 tigestol Drugs 0.000 description 1
229940032666 tiludronate disodium Drugs 0.000 description 1
229960005324 tiludronic acid Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
229960004167 toremifene citrate Drugs 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000017105 transposition Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SK556-2003A 2000-11-27 2001-11-05 EP4 receptor selective agonists in the treatment of osteoporosis SK5562003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25327500P	2000-11-27	2000-11-27
PCT/IB2001/002073 WO2002042268A2 (en)	2000-11-27	2001-11-05	Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number	Publication Date
SK5562003A3 true SK5562003A3 (en)	2004-08-03

Family

ID=22959588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK556-2003A SK5562003A3 (en)	2000-11-27	2001-11-05	EP4 receptor selective agonists in the treatment of osteoporosis

Country Status (41)

Country	Link
US (3)	US6552067B2 (is)
EP (1)	EP1339678B1 (is)
JP (2)	JP3984164B2 (is)
KR (1)	KR20030053063A (is)
CN (1)	CN1476429A (is)
AR (1)	AR035074A1 (is)
AT (1)	ATE374182T1 (is)
AU (1)	AU2002210848A1 (is)
BG (1)	BG107697A (is)
BR (1)	BR0115687A (is)
CA (1)	CA2429850C (is)
CY (1)	CY1106976T1 (is)
CZ (1)	CZ20031257A3 (is)
DE (1)	DE60130675T2 (is)
DK (1)	DK1339678T3 (is)
EA (1)	EA200300379A1 (is)
EC (1)	ECSP034623A (is)
EE (1)	EE200300246A (is)
ES (1)	ES2291361T3 (is)
GT (2)	GT200100238AA (is)
HN (1)	HN2001000266A (is)
HU (1)	HUP0400807A2 (is)
IL (1)	IL155368A0 (is)
IS (1)	IS6775A (is)
MA (1)	MA26961A1 (is)
MX (1)	MXPA03004623A (is)
NO (1)	NO20032360L (is)
NZ (1)	NZ525164A (is)
OA (1)	OA12533A (is)
PA (1)	PA8533901A1 (is)
PE (1)	PE20020637A1 (is)
PL (1)	PL362030A1 (is)
PT (1)	PT1339678E (is)
SI (1)	SI1339678T1 (is)
SK (1)	SK5562003A3 (is)
SV (1)	SV2003000746A (is)
TN (1)	TNSN01166A1 (is)
TW (1)	TW200424170A (is)
UY (1)	UY27038A1 (is)
WO (1)	WO2002042268A2 (is)
ZA (1)	ZA200302803B (is)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ525164A (en) *	2000-11-27	2005-04-29	Pfizer Prod Inc	EP4 receptor selective agonists in the treatment of osteoporosis
ES2254726T3 (es) *	2001-07-16	2006-06-16	F. Hoffmann-La Roche Ag	Analogos de prostaglandina como agonistas receptores de ep4.
EP1408961B1 (en)	2001-07-16	2007-07-11	F. Hoffmann-La Roche Ag	2 pyrrolidone derivatives as prostanoid agonists
CN101921220B (zh)	2001-07-23	2013-05-22	小野药品工业株式会社	治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物
US20040254230A1 (en) *	2001-12-03	2004-12-16	Ogidigben Miller J.	Method for treating ocular hypertension
EP1481976B1 (en)	2002-03-05	2012-11-07	Ono Pharmaceutical Co., Ltd.	8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2003077910A1 (en) *	2002-03-18	2003-09-25	Pfizer Products Inc.	Methods of treatment with selective ep4 receptor agonists
AU2003209571A1 (en) *	2002-03-18	2003-09-29	Pfizer Products Inc.	Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en)	2002-05-14	2003-06-03	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure
US20050239872A1 (en) *	2002-06-06	2005-10-27	Xavier Billot	1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
EP1513523A1 (en) *	2002-06-06	2005-03-16	Merck Frosst Canada & Co.	1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
CA2483555A1 (en) *	2002-06-10	2003-12-18	Applied Research Systems Ars Holding N.V.	Gamma lactams as prostaglandin agonists and use thereof
GB0219143D0 (en) *	2002-08-16	2002-09-25	Univ Leicester	Modified tailed oligonucleotides
EP1563846B1 (en)	2002-10-10	2012-08-29	Ono Pharmaceutical Co., Ltd.	Endogenous repair factor production promoters
AU2003275838A1 (en) *	2002-10-25	2004-05-13	Beunard, Jean-Luc	Pyrrolidin-2-on derivatives as ep4 receptor agonists
WO2004043354A2 (en)	2002-11-08	2004-05-27	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en)	2002-11-08	2007-03-27	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) *	2003-03-26	2006-05-30	Merck & Co. Inc.	EP4 receptor agonist, compositions and methods thereof
BRPI0406717A (pt) *	2003-01-10	2005-12-20	Hoffmann La Roche	Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
WO2004065365A1 (ja) *	2003-01-21	2004-08-05	Ono Pharmaceutical Co., Ltd.	８−アザプロスタグランジン誘導体およびその医薬用途
CA2513652A1 (en)	2003-03-03	2004-09-16	Applied Research Systems Ars Holding N.V.	G-lactam derivatives as prostaglandin agonists
US6734201B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2005012232A2 (en)	2003-07-18	2005-02-10	Applied Research Systems Ars Holding N.V.	Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) *	2003-08-28	2006-04-25	Adolor Corporation	Fused bicyclic carboxamide derivatives and methods of their use
CN1845914A (zh)	2003-09-02	2006-10-11	默克公司	用于治疗眼压过高的眼用组合物
AU2004271978B2 (en)	2003-09-04	2009-02-05	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
AU2004272546B2 (en)	2003-09-04	2007-10-18	Merck Sharp & Dohme Corp.	Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005060946A1 (en) *	2003-12-17	2005-07-07	Pfizer Products Inc.	Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass
US7169807B2 (en) *	2004-04-09	2007-01-30	Allergan, Inc.	10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
CN1988903A (zh)	2004-07-20	2007-06-27	默克公司	用于治疗高眼压症的眼用组合物
WO2006043655A1 (ja) *	2004-10-22	2006-04-27	Ono Pharmaceutical Co., Ltd.	吸入用医薬組成物
JP2008518013A (ja) *	2004-10-26	2008-05-29	アラーガン、インコーポレイテッド	プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
WO2006052630A1 (en) *	2004-11-04	2006-05-18	Allergan, Inc.	Therapeutic substituted piperidone compounds
US7547685B2 (en) *	2004-11-08	2009-06-16	Allergan, Inc.	Therapeutic substituted pyrrolidone compounds
US7101906B2 (en) *	2004-11-16	2006-09-05	Allergan, Inc.	2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en)	2004-11-23	2007-02-27	Allergan, Inc.	2,3,4-substituted cyclopentanones as therapeutic agents
KR100890490B1 (ko) *	2005-01-27	2009-03-26	아사히 가세이 파마 가부시키가이샤	헤테로 6원환 화합물 및 그의 용도
US7531533B2 (en)	2005-01-27	2009-05-12	Asahi Kasei Pharma Corporation	6-Membered heterocyclic compound and use thereof
US7772392B2 (en)	2005-05-06	2010-08-10	Allergan, Inc.	Therapeutic substituted β-lactams
BRPI0611257A2 (pt) *	2005-05-06	2010-08-24	Allergan Inc	beta-lactamas substituÍdas e uso em medicina do mesmo
US7893107B2 (en) *	2005-11-30	2011-02-22	Allergan, Inc.	Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) *	2006-02-15	2006-07-19	(주)아이앤씨	수직형 대형 폐기물 파쇄기
US20070232660A1 (en) *	2006-04-04	2007-10-04	Allergan, Inc.	Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2094839B1 (en)	2006-12-08	2020-02-05	University of Rochester	Expansion of hematopoietic stem cells
EP2465506A1 (en)	2006-12-18	2012-06-20	Allergan, Inc.	Methods and compositions for treating gastrointestinal disorders
AU2008246579A1 (en)	2007-05-08	2008-11-13	National University Corporation, Hamamatsu University School Of Medicine	Cytotoxic T cell activator comprising EP4 agonist
DK2155733T3 (da) *	2007-05-23	2012-10-29	Allergan Inc	Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
US8063033B2 (en) *	2008-01-18	2011-11-22	Allergan, Inc.	Therapeutic beta-lactams
US8202855B2 (en)	2008-03-04	2012-06-19	Allergan, Inc	Substituted beta-lactams
US7705001B2 (en) *	2008-03-18	2010-04-27	Allergan, Inc	Therapeutic substituted gamma lactams
US8404736B2 (en) *	2008-08-14	2013-03-26	Beta Pharma Canada Inc.	Heterocyclic amide derivatives as EP4 receptor antagonists
WO2010116270A1 (en)	2009-04-10	2010-10-14	Pfizer Inc.	Ep2/4 agonists
KR20120093955A (ko)	2009-10-14	2012-08-23	젬머스 파마 인코포레이티드	바이러스 감염에 대한 병용 요법 치료
RU2564414C2 (ru) *	2010-03-08	2015-09-27	Какен Фармасьютикал Ко., Лтд.	Новый агонист ер4
CA2738045C (en)	2010-05-28	2019-02-19	Simon Fraser University	Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) *	2010-06-16	2011-12-21	LEK Pharmaceuticals d.d.	Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en)	2010-08-19	2014-04-15	Allergan, Inc.	Compositions and soft tissue replacement methods
WO2012112757A2 (en)	2011-02-17	2012-08-23	Allergan, Inc.	Compositions and improved soft tissue replacement methods
EP2678022A2 (en)	2011-02-23	2014-01-01	Allergan, Inc.	Compositions and improved soft tissue replacement methods
EP2814526B1 (en)	2012-02-16	2016-11-02	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013123272A1 (en)	2012-02-16	2013-08-22	Allergan, Inc.	Compositions and improved soft tissue replacement methods
EP2814527A1 (en)	2012-02-16	2014-12-24	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013123270A1 (en)	2012-02-16	2013-08-22	Allergan, Inc.	Compositions and improved soft tissue replacement methods
HUE031885T2 (en) *	2012-07-19	2017-08-28	Cayman Chemical Co Inc	Difluoro lactam preparations for EP4-mediated osteo-related diseases and conditions
ES2733998T3 (es)	2012-10-29	2019-12-03	Cardio Incorporated	Agente terapéutico específico de enfermedad pulmonar
WO2014144500A2 (en)	2013-03-15	2014-09-18	Cayman Chemical Company, Inc.	Methods of synthesizing a difluorolactam analog
ES2635635T3 (es) *	2013-03-15	2017-10-04	Cayman Chemical Company, Incorporated	Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
US9676712B2 (en)	2013-03-15	2017-06-13	Cayman Chemical Company, Inc.	Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
KR20160048054A (ko) *	2013-07-19	2016-05-03	카이맨 케미칼 컴파니 인코포레이티드	골 성장의 촉진을 위한 방법, 시스템 및 조성물
KR20160042039A (ko)	2013-08-09	2016-04-18	알데릭스, 인코포레이티드	인산염 수송을 억제하기 위한 화합물 및 방법
US9968716B2 (en)	2013-10-15	2018-05-15	Ono Pharmaceutical Co., Ltd.	Drug-eluting stent graft
US9650414B1 (en)	2014-05-30	2017-05-16	Simon Fraser University	Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
ES2721525T3 (es)	2014-06-06	2019-08-01	Allergan Inc	Novedosos agonistas de EP4 como compuestos terapéuticos
US9540357B1 (en)	2014-07-31	2017-01-10	Allergan, Inc.	15-aryl prostaglandins as EP4 agonists, and methods of use thereof
US10400000B2 (en)	2015-06-12	2019-09-03	Simon Fraser University	Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
AU2017225999B2 (en) *	2016-03-04	2022-08-18	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for muscle regeneration using prostaglandin E2
CN107011377B (zh) *	2017-05-03	2019-02-26	南通书创药业科技有限公司	一种β-羰基磷酸酯的制备方法
US10988468B2 (en) *	2017-12-25	2021-04-27	Asahi Kasei Pharma Corporation	Nitrogen-containing 6-membered cyclic compound
WO2020237096A1 (en)	2019-05-21	2020-11-26	Ardelyx, Inc.	Combination for lowering serum phosphate in a patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1158163A (en)	1966-06-15	1969-07-16	Berk Ltd	Improvements in or relating to Polymer Compositions
ZA72645B (en) *	1971-03-05	1972-11-29	Upjohn Co	Prostaglandin analogs
DE2346706A1 (de) *	1973-09-17	1975-04-03	Hoechst Ag	Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en)	1974-08-06	1976-08-17	E. I. Du Pont De Nemours And Company	1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en)	1975-04-26	1978-09-12	Tanabe Seiyaku Co. Ltd.	8-azaprostanoic acid derivatives
NL7604330A (nl)	1975-04-28	1976-11-01	Syntex Inc	Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de)	1975-06-27	1977-01-13	Hoechst Ag	Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en)	1976-03-31	1979-11-30	Labaz	8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) *	1976-05-04	1977-11-17	Hoechst Ag	Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) *	1976-08-06	1979-12-04	Pfizer Inc.	1,5-Disubstituted-2-pyrrolidones
SE423813B (sv) *	1976-08-06	1982-06-07	Pfizer	Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4320136A (en)	1980-08-11	1982-03-16	E. I. Du Pont De Nemours And Company	8-Aza-16,16-difluoroprostanoids
US4456613A (en)	1982-12-27	1984-06-26	E. I. Du Pont De Nemours And Company	6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (is)	1992-03-05	1996-10-11	Pfizer
SE9302334D0 (sv)	1993-07-06	1993-07-06	Ab Astra	New compounds
ZA944647B (en)	1993-07-06	1995-01-06	Astra Ab	Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
US5955481A (en)	1994-03-28	1999-09-21	Nissan Chemical Industries, Ltd.	Pyridine type thiazolidines
IL113112A (en)	1994-03-28	2000-06-01	Nissan Chemical Ind Ltd	Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5703108A (en) *	1996-02-28	1997-12-30	Pfizer Inc.	Bone deposition by certain prostaglandin agonists
AU6427599A (en) *	1998-10-15	2000-05-01	Merck & Co., Inc.	Methods for stimulating bone formation
CA2346038A1 (en)	1998-10-15	2000-04-20	Merck & Co., Inc.	Methods for inhibiting bone resorption
PL356662A1 (en) *	1999-12-22	2004-06-28	Pfizer Products Inc.	Ep4 receptor selective agonists in the treatment of osteoporosis
PT1132086E (pt) *	2000-01-31	2006-09-29	Pfizer Prod Inc	Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica
US20010056060A1 (en) *	2000-02-07	2001-12-27	Cameron Kimberly O.	Treatment of osteoporsis with EP2/EP4 receptor selective agonists
NZ525164A (en) *	2000-11-27	2005-04-29	Pfizer Prod Inc	EP4 receptor selective agonists in the treatment of osteoporosis
US6573294B1 (en) *	2002-05-14	2003-06-03	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure

2001
- 2001-11-05 NZ NZ525164A patent/NZ525164A/en unknown
- 2001-11-05 BR BR0115687-0A patent/BR0115687A/pt not_active IP Right Cessation
- 2001-11-05 EP EP01978757A patent/EP1339678B1/en not_active Expired - Lifetime
- 2001-11-05 JP JP2002544404A patent/JP3984164B2/ja not_active Expired - Lifetime
- 2001-11-05 PT PT01978757T patent/PT1339678E/pt unknown
- 2001-11-05 ES ES01978757T patent/ES2291361T3/es not_active Expired - Lifetime
- 2001-11-05 HU HU0400807A patent/HUP0400807A2/hu unknown
- 2001-11-05 CZ CZ20031257A patent/CZ20031257A3/cs unknown
- 2001-11-05 SI SI200130776T patent/SI1339678T1/sl unknown
- 2001-11-05 WO PCT/IB2001/002073 patent/WO2002042268A2/en not_active Ceased
- 2001-11-05 DE DE60130675T patent/DE60130675T2/de not_active Expired - Fee Related
- 2001-11-05 AU AU2002210848A patent/AU2002210848A1/en not_active Abandoned
- 2001-11-05 KR KR10-2003-7007109A patent/KR20030053063A/ko not_active Ceased
- 2001-11-05 IL IL15536801A patent/IL155368A0/xx unknown
- 2001-11-05 MX MXPA03004623A patent/MXPA03004623A/es active IP Right Grant
- 2001-11-05 SK SK556-2003A patent/SK5562003A3/sk not_active Application Discontinuation
- 2001-11-05 EA EA200300379A patent/EA200300379A1/ru unknown
- 2001-11-05 CA CA002429850A patent/CA2429850C/en not_active Expired - Fee Related
- 2001-11-05 EE EEP200300246A patent/EE200300246A/xx unknown
- 2001-11-05 CN CNA018194877A patent/CN1476429A/zh active Pending
- 2001-11-05 PL PL01362030A patent/PL362030A1/xx not_active Application Discontinuation
- 2001-11-05 DK DK01978757T patent/DK1339678T3/da active
- 2001-11-05 OA OA1200300141A patent/OA12533A/en unknown
- 2001-11-05 AT AT01978757T patent/ATE374182T1/de not_active IP Right Cessation
- 2001-11-21 US US09/990,556 patent/US6552067B2/en not_active Expired - Fee Related
- 2001-11-23 HN HN2001000266A patent/HN2001000266A/es unknown
- 2001-11-23 UY UY27038A patent/UY27038A1/es not_active Application Discontinuation
- 2001-11-26 TW TW093115078A patent/TW200424170A/zh unknown
- 2001-11-26 AR ARP010105489A patent/AR035074A1/es unknown
- 2001-11-26 PE PE2001001180A patent/PE20020637A1/es not_active Application Discontinuation
- 2001-11-26 SV SV2001000746A patent/SV2003000746A/es unknown
- 2001-11-26 TN TNTNSN01166A patent/TNSN01166A1/fr unknown
- 2001-11-27 GT GT200100238AK patent/GT200100238AA/es unknown
- 2001-11-27 GT GT200100238A patent/GT200100238A/es unknown
- 2001-11-27 PA PA20018533901A patent/PA8533901A1/es unknown
2002
- 2002-12-20 US US10/326,366 patent/US6747054B2/en not_active Expired - Fee Related
2003
- 2003-04-03 BG BG107697A patent/BG107697A/xx unknown
- 2003-04-10 IS IS6775A patent/IS6775A/is unknown
- 2003-04-10 ZA ZA200302803A patent/ZA200302803B/en unknown
- 2003-05-13 MA MA27159A patent/MA26961A1/fr unknown
- 2003-05-26 NO NO20032360A patent/NO20032360L/no not_active Application Discontinuation
- 2003-05-27 EC EC2003004623A patent/ECSP034623A/es unknown
- 2003-09-23 US US10/668,633 patent/US7192979B2/en not_active Expired - Fee Related
2007
- 2007-05-11 JP JP2007127062A patent/JP2007197467A/ja active Pending
- 2007-11-06 CY CY20071101420T patent/CY1106976T1/el unknown

Also Published As

Publication number	Publication date
IS6775A (is)	2003-04-10
DE60130675T2 (de)	2008-01-24
WO2002042268A3 (en)	2002-07-25
NZ525164A (en)	2005-04-29
UY27038A1 (es)	2002-07-31
PL362030A1 (en)	2004-10-18
DE60130675D1 (de)	2007-11-08
ZA200302803B (en)	2004-04-13
US20040259921A1 (en)	2004-12-23
PA8533901A1 (es)	2002-11-28
US6552067B2 (en)	2003-04-22
HN2001000266A (es)	2002-01-30
MXPA03004623A (es)	2003-09-05
AU2002210848A1 (en)	2002-06-03
SV2003000746A (es)	2003-01-13
GT200100238A (es)	2002-06-26
EA200300379A1 (ru)	2003-08-28
US6747054B2 (en)	2004-06-08
WO2002042268A2 (en)	2002-05-30
TW200424170A (en)	2004-11-16
OA12533A (en)	2006-06-05
ES2291361T3 (es)	2008-03-01
SI1339678T1 (sl)	2007-12-31
EP1339678B1 (en)	2007-09-26
JP2007197467A (ja)	2007-08-09
NO20032360L (no)	2003-07-23
GT200100238AA (es)	2004-05-12
CN1476429A (zh)	2004-02-18
EP1339678A2 (en)	2003-09-03
US20020065308A1 (en)	2002-05-30
EE200300246A (et)	2003-10-15
ECSP034623A (es)	2003-07-25
ATE374182T1 (de)	2007-10-15
TNSN01166A1 (fr)	2005-11-10
CA2429850A1 (en)	2002-05-30
CZ20031257A3 (cs)	2004-04-14
JP2004521869A (ja)	2004-07-22
PE20020637A1 (es)	2002-07-18
BR0115687A (pt)	2003-09-09
CY1106976T1 (el)	2012-09-26
DK1339678T3 (da)	2008-02-04
US7192979B2 (en)	2007-03-20
CA2429850C (en)	2008-12-30
BG107697A (en)	2004-01-30
KR20030053063A (ko)	2003-06-27
PT1339678E (pt)	2007-11-30
HUP0400807A2 (hu)	2004-07-28
JP3984164B2 (ja)	2007-10-03
MA26961A1 (fr)	2004-12-20
AR035074A1 (es)	2004-04-14
IL155368A0 (en)	2003-11-23
US20030149086A1 (en)	2003-08-07
NO20032360D0 (no)	2003-05-26

Legal Events

Date	Code	Title	Description
2010-06-07	FC9A	Refused patent application

Publication	Publication Date	Title
CA2429850C (en)	2008-12-30	Ep4 receptor selective agonists in the treatment of osteoporosis
US6642266B2 (en)	2003-11-04	EP4 receptor selective agonists in the treatment of osteoporosis
DE69736007T2 (de)	2006-12-28	Vorbeugung des verlustes und wiederherstellung von knochenmasse unter verwendung von prostaglandin-analogen
US6531485B2 (en)	2003-03-11	Prostaglandin agonists
JPH11180926A (ja)	1999-07-06	骨粗しょう症用化合物
HK1059433A (en)	2004-07-02	Ep4 receptor selective agonists in the treatment of osteoporosis
HK1051366A (en)	2003-08-01	Ep4 receptor selective agonists in the treatment of osteoporosis